Weekly belimumab is associated with greater benefit than placebo for patients with hypocomplementemic/anti-double stranded (ds)DNA-positive systemic lupus erythematosus.
In the absence of an effective pharmacotherapy for systemic sclerosis, researchers suggest stem cell transplant may have potential in the management of cutaneous and internal organ manifestations.
The consideration of additional variables, such as skin biopsy, should be used to involve more patients and prevent the inclusion of any cutaneous diseases that mimic ADM.
Dermatology Advisor Articles
- Natural Products Superior to Synthetic, Dermatologist-Recommended Products for Sensitive Skin
- Liposuction: Reducing Complications As Well As Fat
- Solutions for Hyperhidrosis: Newly Approved Treatments and Research Update
- Pembrolizumab May Be Effective for Advanced Basal Cell Carcinoma
- Treating Chronic Itch: Therapeutic Review
- Use of Bee Venom for Topical Treatment in Patients With Atopic Dermatitis
- Scribes Improve Physician Workflow, Patient Interaction
- Homocysteine, Folate, Vitamin B12 as Potential Biomarkers for Vitiligo
- Amoxicillin Therapy Effective for Treating Inflammatory Acne
- Qbrexza Now Available for the Treatment of Primary Axillary Hyperhidrosis
- Preventative Laser Treatment Could Reduce Postoperative Scarring
- Topical Cantharidin Safe and Effective for Warts and Molluscum Contagiosum
- Change in Shelter Eligibility Policy Tied to More ED Visits
- Without Medicaid Expansion, Poor Patients Forgo Medical Care
- Treatment for WHIM Syndrome Gets Orphan Drug Designation